News

Activation Capital Launches Start-the-Journey: Pre-Accelerator Program

Activation Capital proudly announces the launch of Start-the-Journey, a new BioHealth Pre-Accelerator designed to equip early-stage biotech and life science entrepreneurs with the knowledge and tools to build successful startups. Powered by Fat Robin Consulting, this innovative program supports founders in the initial phases of their entrepreneurial journey, preparing them for more advanced initiatives like Activation Capital’s Frontier BioHealth, launched earlier this year to support scaling advanced-stage startups.

The launch of Start-the-Journey comes as Central Virginia’s biotech and life sciences sector continues to thrive. The region has experienced significant advancements, including the growth of its pharmaceutical manufacturing cluster and an expansion of biotech educational programs at local universities. With local research institutions expanding their biotech offerings, Central Virginia is becoming a recognized hub for life sciences innovation. Activation Capital is committed to supporting this ecosystem by helping early-stage entrepreneurs build a solid foundation through Start-the-Journey and its later-stage program Frontier BioHealth.

“This program provides a foundational experience for entrepreneurs navigating the early challenges of building a biohealth startup. Our goal is to help them develop the essential skills needed to succeed,” said Dr. Jim Pannucci, Vice President of Entrepreneurship at Activation Capital.

The program, with content provided by Fat Robin Consulting, includes a personalized intake session for each startup, offering tailored guidance from experts. Cohorts will operate on a rolling model, starting monthly from October 2024 through January 2025. Participants will cover critical topics such as entrepreneurial qualities, market value creation, MVP development, and key resources for entrepreneurs.

Seema Sood, CEO and Founder of Fat Robin Consulting, expressed enthusiasm for the program: “We’re excited to work with founders who are shaping the future of biotech. A strong foundation on entrepreneurship will scaffold the long-term success of young companies.”

Start-the-Journey is ideal for founders in Richmond, across Virginia, or those considering locating their company in the state, with a focus on deep-tech biotechnology, pharmaceuticals, medical devices, and diagnostics. Offered at no cost, the program is designed to reduce financial burdens for early-stage entrepreneurs, and Activation Capital takes no founder equity.

“We’re excited about the potential impact Start-the-Journey will have in fostering innovation and accelerating the growth of Virginia’s BioHealth sector,” Pannucci added. Additional information can be found at https://activation.capital/start-the-journey/.

Start-the-Journey is funded in part through a grant with the U.S. Small Business Administration (SBA). All opinions, conclusions, and/or recommendations expressed herein are those of Activation Capital and do not necessarily reflect the views of the SBA.

Learn more here.

Recent News

04/08/2026

Likarda and The Tiny Cargo Company Announce Strategic Partnership to Advance Next-Generation Delivery of Biologics, Peptides and Small Molecules

Likarda, Inc., a leader in hydrogel-based drug delivery technologies, today announced a strategic partnership with Tiny Cargo, an innovator in extracellular vesicle (EV) delivery systems. The collaboration will focus on advancing the delivery of biologics and small molecules by integrating Likarda’s Core-Shell Spherification® (CSS®) platform with Tiny Cargo’s vesicle-based technologies. The partnership is designed to

04/08/2026

ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the closing of an oversubscribed $40 million financing. This brings the total capital raised to date to more than $150 million.

04/02/2026

ATCC Receives New CDC Award to Help Fast-track Diagnostic Tests for Future Disease Outbreaks

TCC has been selected by the Centers for Disease Control and Prevention (CDC) Office of Readiness and Response (ORR) for a new five-year contract to support rapid test development during public health emergencies. The award, valued at up to $148 million (IDIQ contract 75D301-25-R-73207), will help ensure that diagnostic tools can be quickly created, validated,